ADAM17 and uterine carcinosarcoma: In this study, ADAM17 was found to be expressed in 57 cases of uterine carcinosarcoma with the highest mutation frequency (10.53%), while it was barely expressed in 511 cases of kidney renal clear cell carcinoma with a mutation rate of 0.39%.